The Medical Advisor

Parkinson’s disease, a progressive neurodegenerative disorder, affects millions worldwide, causing debilitating symptoms like tremors, rigidity, and cognitive decline. As researchers continue to explore innovative treatments, one unexpected candidate has emerged: ivermectin, a drug traditionally used to treat parasitic infections. Recent studies have sparked curiosity about its potential neuroprotective effects, prompting questions about whether this widely available medication could offer hope for managing or even slowing the progression of Parkinson’s disease. In this article, we delve into the science behind ivermectin’s potential role in Parkinson’s treatment, examining the latest research, mechanisms of action, and what this could mean for patients seeking new therapeutic options. Can Ivermectin play a key role in treating Parkinson's Disease? Two peer-reviewed papers—one by Warnecke et al. (2020) and another by Wadsworth et al. (2024)—along with a 2021 PhD thesis by ...

Neurodegenerative diseases such as Alzheimer’s disease, Parkinson’s disease, ALS, and vascular dementia represent one of modern medicine’s greatest unmet challenges. Despite decades of research and billions of dollars invested, disease-modifying therapies remain limited, expensive, and often marginal in benefit. This has driven growing interest in repurposed drugs —existing medications originally developed for other conditions that may influence neurodegeneration through mitochondrial, metabolic, inflammatory, or protein-aggregation pathways. Some repurposed candidates show promise. Many fail. A few persist in a gray zone between compelling biology and inconclusive clinical evidence. This pillar page provides a clear, evidence-based framework for understanding repurposed neurodegenerative therapies—what they target, how strong the evidence is, and how to separate legitimate research from hype. What Are Repurposed Neurodegenerative Therapies? Drug repurposing (also called drug repositio...

Executive Brief Modern oncology is constrained by a paradox: Clinical trials are the gold standard. Yet they are structurally incapable of testing most  biologically plausible treatment combinations. Metabolic therapies, repurposed drugs, dietary interventions, and immune-modulating strategies form a  combinatorial space too large, too unprofitable, and too complex  for conventional trial frameworks. This is where  AI-driven simulations  become essential.  AI-driven simulations  offer a way to prioritize biologically plausible combinations, generating hypotheses about how existing drugs and metabolic interventions might work together before any formal clinical trial begins. These models do not replace trials, but they help focus limited research resources on the most promising leads.  This report synthesizes: Cancer metabolism Immune energetics Repurposed drug mechanisms Immunothera...

Introduction: The Rise of Metabolic Therapy in Cancer Care The field of oncology is generally based on three treatment areas: medical oncology, radiation oncology, and surgical oncology. However, another area is looming on the horizon, quickly gaining traction as a new and exciting frontier of cancer treatment. Metabolic oncology, also known as cancer metabolism, focuses on how cancer cells use energy and nutrients differently than normal cells. Scientists working in metabolic oncology look for targets in these metabolic processes to create treatments that can specifically attack cancer cells while protecting healthy cells. Leading researchers have discovered innovative ways to prevent diseases from spreading and drastically improve patient outcomes. A groundbreaking approach is emerging in oncology that targets cancer cell metabolism. This innovative strategy targets the unique way cancer cells process energy and nutrients, offering new hope for patients and clinicians alike. As ...